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STUDY PROTOCOL
An intrapleural administration 
of zoledronic acid for inoperable malignant 
mesothelioma patients: a phase I clinical study 
protocol
Yuji Tada1, Kenzo Hiroshima2, Hideaki Shimada3, Masato Shingyoji4, Toshio Suzuki1, Hiroki Umezawa1, 
Ikuo Sekine5, Yuichi Takiguchi6, Koichiro Tatsumi1 and Masatoshi Tagawa7,8*
Abstract 
Background: The third generation of bisphosphonates is clinically in use for patients of osteoporosis or malignancy-
linked hypercalcemia. The agents can also produce anti-tumor effects on bone metastasis of several types of tumors. 
We recently found that one of the agents achieved cytotoxicity to mesothelioma in vitro and in an orthotopic animal 
model. Mesothelioma is resistant to a number of chemotherapeutic agents, and suppression of local tumor growth is 
beneficial to the patients since metastasis to extra-thoracic organs is relatively infrequent until a late stage.
Methods/design: We demonstrated in an orthotopic mouse model that an intrapleural but not intravenous injec-
tion of zoledronic acid, one of the third generation bisphosphonates, at a clinically equivalent dose suppressed the 
tumor growth. Nevertheless, a high concentration of zoledronic acid administrated in the pleural cavity produced 
pleural adhesion. We also showed that zoledronic acid produced synergistic cytotoxic effects with cisplatin, the first-
line chemotherapeutic agent for mesothelioma. We then planned to conduct a phase I clinical study to investigate 
any adverse effects and a possible clinical benefits produced by an intrapleural administration of zoledronic acid to 
mesothelioma patients who became resistant to the first-line chemotherapeutic agents. The clinical trial is a dose 
escalation study starting with 0.4, 1, 4, 8 and 16 mg per person since safety of administration of zoledronic acid into 
the pleural cavity remains unknown. Each dose group consists of three persons and the protocol allows to repeat 
administration of the same dose into the pleural cavity at a 4-weeks interval.
Discussion: We will conduct a possible combinatory study of intrapleural administration of zoledronic acid and sys-
temic administration of the first-line agent to a chemotherapy-naïve patient based on the maximum tolerance dose 
of zoledronic acid determined by the present clinical trial. We propose that administration of bisphosphonates in a 
closed cavity is a treatment strategy for tumors developed in the cavity probably through the direct cytotoxic activity.
Trial registration: UMIN clinical trials registry, Japan. Register ID: UMIN8093.
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Background
Malignant mesothelioma is often associated with occupa-
tional usage of asbestos in the patient’s history but some 
cases are also linked with non-occupational exposures 
(Carbone et al. 2002; Robinson et al. 2005; Porpodis et al. 
2013; Røe and Stella 2015). A majority of mesothelioma 
develop from pleura and malignant pleural mesothe-
lioma invades along the cavities even in an early phase. 
The invasiveness consequently suppresses functions of 
vital organs in the pleural cavity, resulting in respira-
tory and cardiac failure. Nevertheless, distant metastasis 
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to extrathoracic organs is relatively infrequent until the 
late stage, indicating that suppression of the local tumor 
growth can be beneficial to the patients.
Mesothelioma is resistant to current multimodal treat-
ments (Opitz 2014; Kotova et  al. 2015). Extrapleural 
pneumonectomy is one of the standard surgical options 
for an early-staged case, but recurrence is often common. 
Moreover, quality of the patient life deteriorates due to 
the extensive operation procedure. Mesothelioma is not 
suitable for radiotherapy because a high dose radiation is 
required and a wide radiation area causes pneumonitis. 
It is subsequently used for a palliative purpose. Chemo-
therapy is currently the primary treatment in most of 
the cases, and a combination of cisplatin (CDDP) and 
pemetrexed (PEM) is the first-line chemotherapeutic 
regimen. Nevertheless, the mean survival period with the 
combination is 12.1 months (Vogelzang et al. 2003) and 
no second-line regimen has yet been established for more 
than 10  years. Many clinical trials with different anti-
cancer agents including molecular target agents did not 
show any improvement in the survival (Tada et al. 2015). 
A new therapeutic agent is therefore required to improve 
the prognosis.
Detection of mesothelioma at an early stage is often 
difficult, and differential diagnosis from other cancerous 
and non-cancerous diseases needs careful pathological 
examinations including an immunohistochemical stain-
ing with several kinds of antibody. The latent period 
after asbestos exposure is long, more than 30 years in an 
average, and a medical procedure to prevent the tumor 
development is currently unavailable. Many industrial 
countries have terminated to use asbestos, but emerging 
countries especially in Asia rather increase asbestos con-
sumption due to their economic development (Lin et al. 
2007).
We recently demonstrated that the third generation of 
bisphosphonates, zoledronic acid (ZOL), achieved anti-
tumor effects on mesothelioma (Okamoto et  al. 2012). 
The agent induced cell cycle arrest and apoptosis in mes-
othelioma through inhibiting functions of small G pro-
teins and the activity of topoisomerase II (Okamoto et al. 
2014). ZOL treatments also augmented p53 expression 
levels in mesothelioma bearing the wild-type p53 gene 
and the increased p53 expression contributed to syner-
gistic combinatory cytotoxicity by ZOL and CDDP (Oka-
moto et  al. 2013). These data suggested that ZOL was 
one of the potential candidates for mesothelioma treat-
ments. ZOL is currently used for osteoporosis and for 
malignancy-induced hypercalcemia in a clinical setting. 
The agent tends to accumulate in bone tissues and blocks 
activities of osteoclasts, resulting in lowering serum cal-
cium concentrations (Yuasa et  al. 2007). Previous stud-
ies demonstrated that ZOL also suppressed metastasis of 
breast and prostate cancer to bone tissues (Climent et al. 
2013; Mathew and Brufsky 2015). We then examined a 
possible anti-tumor effects of ZOL in vivo and found that 
a systemic administration of ZOL failed to achieve anti-
tumor effects on subcutaneous mesothelioma (Fig.  1). 
In contrast, an intrapleural injection of ZOL suppressed 
mesothelioma developed in the pleural cavity (Okamoto 
et  al. 2012). Furthermore, an administration of ZOL in 
the pleural cavity produced combinatory anti-tumor 
effects with CDDP in the orthotopic animal model (Oka-
moto et al. 2013). These preclinical studies suggested that 
an intrapleural administration achieved a high concentra-
tion of ZOL enough to produce cytotoxic effects, which 
prompted us to conduct a clinical trial to examine safety 
and possible clinical benefits of ZOL administered into 
the pleural cavity. We therefore planed a phase I study at 
Chiba University Hospital, Chiba, Japan, for inoperable 
and chemotherapy-failed mesothelioma patients. We 
showed our clinical protocol and some of preclinical data 
regarding the safety of ZOL injected into an intrapleural 
cavity.
Efficacy of intrapleural administration of ZOL 
for mesothelioma
We examined possible anti-tumor effects of intrapleural 
injection of ZOL in an orthotopic animal model, human 
mesothelioma tumors inoculated in the thoracic cavity of 
BALB/c nude mice (Table 1). All the animal experiments 
described were approved by the animal experiment and 
welfare committee at Chiba Cancer Center Research 
Institute and Chiba University. Administration of ZOL 
into the intrapleural cavity suppressed the tumor devel-
opments with a dose-dependent manner irrespective of 
tumor cells inoculated. Body weights of mice injected 
with MSTO-211H cells were greater in the ZOL-treated 
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Fig. 1 Growth of subcutaneous tumors developed in BALB/c mice. 
MSTO-211H cells (3 × 106) were subcutaneously inoculated and the 
mice were injected with PBS or ZOL (15 or 50 μg) in the intraperito-
neal cavity twice a week after day 11. Tumor volume was calculated 
according to the formula (1/2 × length × width2). The tumor 
volumes were not statistically different at any time in any groups. The 
average and SE bars are shown (n = 6)
Page 3 of 8Tada et al. SpringerPlus  (2016) 5:195 
group than in control group. The differential body 
weights changes seemed to reflect extension of tumors 
and subsequent emaciation processes. A decreased body 
weight gain is one of the indicators to estimate possible 
toxicity and these data indicated that ZOL administra-
tion did not cause serious adverse reactions. Growth 
of MSTO-211H cells in  vitro was faster than that of 
EHMES-10 cells, which was attributable to greater tumor 
weights of MSTO-211H cells than EHMES-10 cells.
We also calculated a mouse dose equivalent to the 
human dose that was clinically in use. Provided that an 
average body weight of a human and a mouse are 60 kg 
and 20 mg, respectively, 4 mg of ZOL, the human clinical 
dose, corresponds to 16,4 μg in mouse with a conversion 
equation (Reagan-Shaw et  al. 2008). We observed sup-
pression of tumor growth at 15 μg of ZOL in an ortho-
topic animal model with EHMES-10 cells (Table 1). These 
data suggested that 4  mg of ZOL suppressed growth of 
mesothelioma in the pleural cavity. The plasma concen-
trations at 6 and 24 h after an intravenous administration 
of 4  mg ZOL were about 10 and 2  ng/ml, respectively 
(open data from Novartis, ZOMU00007). Supposing 
that 4 mg ZOL is injected into the intrapleural cavity of 
a patient with 1000 ml pleural effusion, the concentration 
in the pleural cavity is 4  μg/ml. The concentration was 
significantly higher than the plasma concentration when 
the same amount of ZOL was used. Our previous cyto-
toxicity data in vitro showed that ZOL at more than 3 μg/
ml in the concentration achieved growth suppression of 
all the human mesothelioma cells tested (Okamoto et al. 
2012). These data collectively indicated that the current 
clinical dose of ZOL, when injected in the pleural cavity 
of an effusion-positive case, could produce anti-tumor 
effects.
Another possible mechanism of ZOL in the anti-
tumor effects in vivo is associated with activated immune 
responses. ZOL inhibits farnesyl pyrophosphate synthase 
in the mevalonate pathway, and subsequently increases 
concentrations of isopentenyl pyrophosphate and 
triphosphoric acid I-adenosine-50-yl ester 3-(3-meth-
ylbut-3-enyl) ester (ApppI), an ATP analogue, in the 
treated tumor cells. These molecules contain a binding 
motif of T cell receptor complexes of γδ Τcells (Wada 
et al. 2014). Consequently, γδ Τcells bearing the Vγ9 Vδ2 
T cell receptors were activated by ZOL-treated cells 
(Benzaid et  al. 2011) and kill the ZOL-treated tumors 
with interferon (IFN)-γ secretion (Märten et  al. 2007). 
Nevertheless, a precise mechanism how the activated 
human γδ Τcells produce cytotoxicity to the tumors 
remains uncharacterized.
Preclinical study for safety in intrapleural administration
Administration of ZOL in the pleural cavity has not been 
examined in human being. A high concentration of ZOL 
may produce adverse reactions since ZOL can induce 
inflammatory responses by producing proinflammatory 
cytokines (Scheller et al. 2011). A clinical study was con-
ducted for gastric cancer patients with malignant ascites 
with intraperitoneal injection of ZOL at 1 mg for priming 
cytotoxic γδ Τcells (Wada et al. 2014). The study showed 
Table 1 Inhibited tumor growth and body/heart weights after an intrapleural injection of ZOL
BALB/c nude mice were inoculated with human mesothelioma, MSTO-211H cells (experiment 1, 2 and 4) or EHMES-10 (experiment 3) (1 × 106 /mouse), in the 
intrapleural cavity and were injected with PBS or ZOL (100 μl in volume) on day 3 or 10. Tumor weights were measured on the indicated day and the averages with 
standard errors are shown (experiment 1; n = 5, experiment 2; n = 6, experiment 3; n = 7, experiment 4; n = 7)
** P < 0.01; * P < 0.05 (experiment 3; difference of tumor weights is statistically significant in any of two groups and that of heart weights is statistically significant only 
between ZOL 15 μg- and ZOL 40 μg-injected groups)
Agent (μg/mouse) Day of agent  
administration
Tumor weight  
(average ± SE) (mg)
Body weight (average ± SE)  
(g)
Heart weight (average ± SE) 
(mg)
Experiment 1 (assessment of tumor weight: day 28)
 PBS 3 491.1 ± 68.4** ND ND
 ZOL (80 μg) 3 0** ND ND
Experiment 2 (assessment of tumor weight: day 28)
 PBS 3 384.8 ± 36.8** 15.9 ± 5.1** 99.8 ± 5.2*
 ZOL (40 μg) 3 19.8 ± 7.2** 18.9 ± 0.24** 114.5 ± 3.6*
Experiment 3 (assessment of tumor weight: day 35)
 PBS 3 197.7 ± 22.9** 18.5 ± 1.0 123.2 ± 5.8
 ZOL (40 μg) 3 2.5 ± 1.2** 19.6 ± 0.3 129.5 ± 3.5*
 ZOL (15 μg) 3 79.3 ± 13.2** 19.2 ± 0.2 116.6 ± 3.4*
Experiment 4 (assessment of tumor weight: day 28)
 PBS 10 377.9 ± 13.3* 16.1 ± 0.4* ND
 ZOL (40 μg) 10 188.6 ± 62.1* 19.2 ± 0.5* ND
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that the ZOL administered into the peritoneal cavity did 
not clinically produce any adverse effects but induced 
recruitment of neutrophil in the peritoneal cavity. Norton 
et al. (2012) also reported that alendronate, an US Food 
and Drug Administration-approved bisphosphonate, 
induced inflammatory reactions in the peritoneal cavity 
in mice. We thereby investigated possible adverse effects 
induced by intrapleural injections of ZOL with BALB/c 
nude mice. Administration of 80  μg ZOL in 100  μl of 
phosphate-buffered saline (PBS) produced adhesion 
between pleura and pericardium in a majority of the mice 
tested, but 40  μg of ZOL did not induce the adhesion. 
Heart weights also increased in mice injected with ZOL 
at 40 μg (experiment 2) on day 28 compared with those 
with PBS, but the mild cardiomegaly was not detected on 
day 35 (experiment 3). An average heart weight of mice 
that received ZOL at 15 μg was even lower than that of 
mice injected with PBS. The mechanism of weight gain of 
heart in mice is unknown but it may be associated with a 
possible congestive heart failure listed as one of the seri-
ous adverse effects of ZOL in human.
We also pathologically examined pleura of mice 
injected with ZOL or PBS as a control (Fig.  2). Treat-
ments with ZOL at 40 μg in 100 μl of PBS did not show 
any cellular infiltrations in pleura, adipose tissues and 
muscles beneath the pleura. We did not find inflamma-
tory reactions and furthermore, the histological features 
were not different from those of PBS-injected mice. 
These data indicated that ZOL less than 0.4 μg/μl at the 
concentration was safely used in mice.
Administration of anti-cancer agents into the pleu-
ral cavity are relatively uncommon but previous studies 
showed that an injection of the chemotherapeutic agent 
into the pleural cavity could be conducted safe (Jones 
et al. 2010; Baba et al. 2013). Constant lung movements 
also facilitate contact and spread of an agent to mesothe-
lioma. Nevertheless, it is unclear whether administration 
into the intrapleural cavity maintains a relative high con-
centration of an agent and induces less frequent systemic 
toxicity compared with an intravenous administration 
in malignant pleural diseases. A drug concentration in 
the pleural cavity is influenced not only by an amount 
of pleural effusion but also by pleural pathophysiologi-
cal conditions that were controlled by invasion levels of 
malignancy. Clinical studies with ZOL for hypercalce-
mia associated with malignancy, multiple myeloma or 
metastatic bone lesion, showed that a majority of ZOL-
induced adverse effects was fever, general malaise, hypoc-
alcemia and hypokalemia. The serious adverse effects 
include acute renal failure, congestive heart failure and 
osteonecrosis of the jaw, but the frequency of these seri-
ous reactions was less than 1 % of the cases. The planned 
a phase I study nevertheless needs to pay attention to the 
above adverse effect as for safety.
Study design and objectives
The phase I study design is to administer ZOL in 100 ml 
saline solution into the pleural cavity of mesothelioma 
patients who are not suitable for a surgical operation 
and fail to respond to the first-line chemotherapeutic 
agents (Fig. 3). It is a dose escalation study with ZOL at 
0.4, 1, 4, 8, 12, 16 mg per person in a single injection and 
three patients are included in each dose group. The pro-
tocol allows to repeatedly use the same ZOL dose for a 
4-weeks interval when the patient wants to receive it and 
is compatible with the inclusion criterial described below. 
The observation period in the current protocol is 14 days 
as for the safety, but we also follow up them until day 28 
for the efficacy and continue to see them at a 4-weeks 
internal thereafter in our outpatient clinic. Escalation to 
the next dose is dependent on the frequency of adverse 
effects. Three more patients need to be enrolled when 1 
patient in a group has an adverse effect greater than the 
grade 3 level of the common terminology criteria for 
adverse events (CTCAE) ver 4.0, and the clinical study 
must to be terminated when more than two patients out 
of total six cases have adverse effects in the same dose 
group.
Fig. 2 Histological pictures of parietal mesothelium of BALB/c nude mice injected with a PBS or b ZOL (40 μg) on day 25. Hematoxylin and eosin 
staining with ×20 magnifications
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The primary endpoints are to investigate a safety level 
of ZOL injected into the pleural cavity, which includes 
to define the maximum tolerance dose and to clarify any 
adverse effects produced according to CTCAE ver 4.0. 
The secondary endpoints are evaluation of anti-tumor 
effects based on tumor volumes, amounts of pleural 
effusion estimated with radiological imaging, and any 
improvements of the patients’ quality of life and the per-
formance status. The tumor volume is assessed with the 
modified Response Evaluation Criteria in Solid Tumors 
(Byrne and Nowak 2004; Labby et al. 2012), and the sub-
jective pain condition is measured with a visual analogue 
scale. Evaluation of the anti-tumor effects will be con-
ducted on day 14 and also on day 28 when the patient 
does not receive any treatments. The clinical protocol 
was approved by the institutional review board of the 
Chiba University Hospital (G23070) and that of Graduate 
School of Medicine, Chiba University (TIBADAI-IN No: 
205), and was registered at UMIN clinical trials registry, 
Japan (UMIN 8093).
Subject selection and withdrawal
Inclusion criteria
Patients eligible for the study are those who are patho-
logically diagnosed as malignant pleural mesothelioma of 
locally advanced or recurrent cases, and not suitable for 
surgical resection. Those refuse to undergo the surgery 
irrespective of their clinical stages are also eligible. In 
addition, the patients who become refractory to chemo-
therapy or decline to receive chemotherapeutic agents are 
eligible. Patients, aged between 20 and 80 years old, must 
be fully explained about the study using a document and 
give a written informed consent. Patients must have pleu-
ral effusion to have an enough space in the pleural cavity 
where ZOL is injected. The Eastern Co-operative Oncol-
ogy Performance status must be between 0 and 2. Life 
expectancy of the patients will be longer than 3 months. 
Patients need to have adequate physiological functions in 
major organs and the laboratory findings must be as fol-
lows: white blood cell; ≧3000/mm3 or neutrophil; ≧1500/
mm3, platelet; ≧1 × 105/mm3, hemoglobin; ≧8.0/dl, total 
bilirubin; ≦1.5 mg/dl, aspartate transaminase and alanine 
aminotransferase; ≦100 IU/l, creatinine; ≦1.5 mg/dl, cre-
atinine clearance; ≧60 ml/min; partial pressure of oxygen 
in arterial blood; ≧60  Torr or SPO2 (breathing in room 
air) ≧90 %, electric cardiogram; within normal range.
The principle investigators and the medial collabora-
tors including those responsible for monitoring the cur-
rent study must approve that the patient is in an adequate 
condition to be enrolled in the study.
Exclusion criteria
Patients with a different tumor other than mesothelioma, 
either synchronous or metachronous, are not eligible 
unless they are completely cured or their progression 
free interval is longer than 2  years. Patients who have 
symptomatic brain metastatic foci or those who require a 
treatment for the brain metastasis are excluded. Patients 
who do not have an enough intra-thoracic space for ZOL 
injection or have participated in other clinical trial(s) with 
approved or unapproved medicine within 4 weeks before 
the entry of this study are not allowed to be enrolled. 
day 1 day 28
ZOL
Follow-up 
day 14
day 1 day 28
ZOL
Follow-up 
day 14 day 1 day 28
ZOL
Follow-up 
day 14 day 1 day 28
ZOL
Follow-up 
day 14
Chemotherapy
day 1 day 28
ZOL
Follow-up 
day 14 day 1 day 28
ZOL
Follow-up 
day 14
Follow-up
Follow-up
Follow-up
Fig. 3 A schematic design of the clinical study. The examination for safety ends 14 days after the ZOL injection but the patient are followed up for 
the efficacy until day 28 and every 4 weeks thereafter. The patient can repeatedly receive ZOL in the pleural cavity at a 4-weeks interval
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Those who are scheduled to receive another anti-cancer 
drug(s) during the study period and those who received 
pleurodesis or radiation within 1 month as a mesotheli-
oma treatment are excluded. Patients who have intersti-
tial pulmonary diseases and pulmonary fibrosis judged by 
chest computed tomographic scanning are not eligible. 
Patients who had myocardial infraction before 6 months 
at the entry and still have a risk of possible recurrence, 
who have experienced allergic reactions or adverse effects 
greater than the grade 3 level of CTCAE ver 4.0 following 
ZOL or other bisphosphonates administrations, and who 
have dental diseases that require invasive treatments are 
not eligible.
Those who have some factors that can prevent good 
compliance with the study protocol and the follow-up 
schedules, including some psychiatric, psychological, 
familial, social or geographical issues, are regarded as not 
being suitable for the study. Patients who are judged as 
inappropriate to participate in the study by the principal 
investigators and the collaborators are excluded.
Discussion
The study is planned to investigate possible adverse 
effects and clinical benefits produced by an intrapleural 
injection of ZOL to malignant pleural mesothelioma 
patients. The bisphosphonates have not yet been admin-
istered into the pleural cavity of human being and our 
preclinical study indicated that a high concentration of 
ZOL induced adhesion in pleura and pericardium prob-
ably due to some inflammatory reactions. An intravenous 
administration of ZOL produced benefits to several types 
of cancer patients with bone metastasis although contro-
versial data about the efficacy were also reported (Zekri 
et al. 2014). The mechanism underlying the possible anti-
tumor effects was linked with accumulation of ZOL in 
bone tissues since the effects were not produced against 
tumors developed in or metastasized to non-osseous 
sites. In contrast, the present clinical protocol aims to 
examine the direct cytotoxicity of ZOL at a high concen-
tration in non-osseous tissues.
A previous study reported that ZOL plasma concentra-
tions rapidly declined with half-lives of 0.2 h (Chen et al. 
2002). The maximum plasma concentration achieved by 
an intravenous injection of 4 mg ZOL did not reach to a 
concentration that was required to kill mesothelioma cell 
lines in vitro. In contrast, an intrapleural administration 
in an orthotopic mouse model can achieve the concen-
tration necessary to stop cell proliferation in  vitro and 
in fact we demonstrated the anti-tumor effects in  vivo. 
A clinical application of the intrapleural administration 
needs to consider two factors, possible inflammatory 
reactions that may be associated with adverse reactions 
and maintenance of a ZOL concentration in the pleural 
cavity. An intrapleural concentration of ZOL is crucial 
for the adverse effects as well as growth inhibitory activ-
ity, but the concentration is difficult to estimate because 
of difficulty to assess a volume of pleural effusion. More-
over, we cannot determine tissue distributions of ZOL 
since an enzyme-linked immunosorbent assay for ZOL is 
currently unavailable. Continuously monitoring of ZOL 
concentrations in the pleural cavity is not clinically prac-
tical. The current phase I trial is thereby a dose escalation 
study to investigate possible adverse reactions according 
to CTCAE ver 4.0 and compared with those in the case 
of an intravenous administration. Several serious adverse 
effects such as acute renal failure, congestive heart failure 
and osteonecrosis of the jaw reported in the intravenous 
injection will be also carefully monitored in this clinical 
trial. In clinical settings, an intravenous injection of ZOL 
induces some of inflammatory reactions including fever, 
general malaise and flu-like syndrome. Bisphosphonates 
in fact can activate non-specific immune responses 
accompanied by neutrophil chemotaxis and relevant 
cytokine productions (Scheller et al. 2011; Norton et al. 
2012; Wada et al. 2014), which may be linked with pleu-
ral and pericardial adhesion observed in our preclinical 
study. Wada et  al. (2014) conducted a clinical trial for 
patients with peritoneal dissemination by administering 
Vγ9 Vδ2 T cells and 1 mg of ZOL into the peritoneal cav-
ity to activate the γδ T cells. They demonstrated that a 
ZOL concentration in ascites fluid was greater and sus-
tained for longer period in the intraperitoneal cavity than 
in the intravenous injection. The study also showed that 
granulocytes were recruited in the peritoneal cavity and 
the patients had low-grade fever. It is currently unknown 
whether these non-specific inflammation reactions were 
due to ZOL administration since the γδ T cells were 
administered at the same time and IFN-γ was also pro-
duced by the activated γδ T cells.
Cytotoxicity of ZOL against mesothelioma is ascrib-
able to several mechanisms including inhibition of small 
G proteins and topoisomerase II activity (Okamoto et al. 
2012, 2014). The ZOL-induced cell death was associated 
with apoptotic processes but not linked with autophagy, 
and many factors were involved in the cell death pro-
cesses. An ATP analogue of ApppI which was produced 
by a feedback mechanism, mediated by ZOL-induced 
depletion of isoprenoid and subsequent enhancement of 
the mevalonate pathway, could play a role in the apopto-
sis, and ZOL-mediated Rab inhibition also contributed 
to the cell death process (Okamoto et  al. 2014). Dis-
rupted actin fiber structures after ZOL treatments were 
caused by suppressed Rho functions and consequently 
induced cell detachment followed by cell death (Oka-
moto et al. 2014). Moreover, mesothelioma treated with 
ZOL showed augmented p53 expression levels and the 
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p53 phosphorylation when the p53 genotype was wild-
type (Okamoto et  al. 2012). The augmentation further 
increased sensitivity to CDDP, the first-line agent for 
mesothelioma. These data collectively indicate that ZOL 
produces anti-tumor responses to mesothelioma when 
they are directly contacted with the agent in vivo.
Mesothelioma is histologically classified into three sub-
types, epithelioid, biphasic and sarcomatoid types. Sen-
sitivity to chemotherapy is different among the subtypes 
and prognosis of sarcomatoid type is in general the worst 
because of the resistance to chemotherapeutic agents. 
A recent study interestingly suggested a polyclonal ori-
gin of mesothelioma, which may reflect the differen-
tial chemosensitivity among the types (Comertpay et al. 
2014). Consequently, the prognosis depends on a ratio 
of heterogeneity within tumors. A clinical response to 
ZOL can be linked with the histological subtypes and 
is differentially influenced by the dependency on small 
G proteins for the cell growth and on production of the 
cytotoxic ATP analogue. The present study however does 
not take the histological classification into considera-
tion because of limited numbers of the enrolled patients. 
Moreover, our previous cytotoxic study in vitro showed 
that ZOL sensitivity was not correlated with histologi-
cal types of the cell lines (Okamoto et al. 2012). Stimula-
tion of immune responses through the γδ T cells with the 
specific T cell receptors is another interesting point for 
investigation. The present study however will not inves-
tigate the activation of the γδ T cells since detection of 
the T cells in peripheral blood cells and regional lymph 
nodes needs careful examinations, which include a time-
course study and exclusion of non-specific T cell activa-
tions by inflammatory cytokines.
In conclusions, the present study plan is to evaluate 
safety and efficacy of ZOL administered in the pleural 
cavity. Confirmation of the safety will lead us to possible 
subsequent clinical studies, which can be a combinatory 
use of ZOL and the first-line chemotherapy to a chemo-
therapy-naïve patient, and a phase II study with the same 
protocol using the maximum tolerance dose of ZOL.
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